Obstetrics & Gynecology:
Tranexamic Acid Treatment for Heavy Menstrual Bleeding: A Randomized Controlled Trial
Lukes, Andrea S. MD, MHSc; Moore, Keith A. PharmD; Muse, Ken N. MD; Gersten, Janet K. MD; Hecht, Bryan R. MD; Edlund, Måns MD, PhD; Richter, Holly E. PhD, MD; Eder, Scott E. MD; Attia, George R. MD, MBA; Patrick, Donald L. PhD, MSPH; Rubin, Arkady PhD; Shangold, Gary A. MD
From the Carolina Women's Research and Wellness Center, Durham, North Carolina; Xanodyne Pharmaceuticals, Inc., Newport, Kentucky; the Department of Obstetrics and Gynecology, University of Kentucky, Lexington, Kentucky; the New Age Medical Research Corporation, Miami, Florida; the Cleveland Clinic Fertility Center, Canfield, Ohio; the Department of Obstetrics and Gynecology, Danderyds Hospital, Stockholm, Sweden; the University of Alabama at Birmingham, Birmingham, Alabama; The Center for Women's Health & Wellness, LLC, Plainsboro, New Jersey; the University of Miami, Miami, Florida; the University of Washington, Seattle, Washington; and ARSTAT Analysis, Flemington, New Jersey.
For a list of investigators who enrolled patients in this study, see the Appendix online at http://links.lww.com/AOG/A198.
Supported by Xanodyne Pharmaceuticals, Inc., and Ferring Pharmaceuticals, Inc.
The authors thank The JB Ashtin Group, Inc., for editorial assistance.
Presented in part at the 57th and 58th annual clinical meetings of the American College of Obstetricians and Gynecologists, May 2–6, 2009, Chicago, Illinois, and May 15–19, 2010, San Francisco, California.
Corresponding author: Andrea S. Lukes, MD, MHSc, Carolina Women's Research and Wellness Center, 249 E. Highway 54, Suite 330, Durham, NC 27713; e-mail: email@example.com.
Financial Disclosure Dr. Lukes receives or has received research support from Xanodyne, Ethicon, Merck, Bayer, Luitpold, Hologic, National Improvement for Women's Healthcare, Duramed, the National Institutes of Health, the Centers for Disease Control and Prevention/Association for Prevention Teaching and Research, Smith & Nephew, Trent Foundation, and American Medical Systems. She consults with and/or has served on speakers' bureaus for Ferring, Xanodyne, Hologic, American Medical Systems, Bayer, Interlace Medical, Ethicon, Boehinger Ingelheim, Myriad, Microsulis (5 years ago), AMAG (4 years ago), and Daichii. She has given expert testimony regarding U.S. Food and Drug Administration approval. Drs. Moore and Shangold are employees of Xanodyne. Dr. Muse receives or has received research support from Amgen, BioSante Pharmaceuticals, Wyeth Research, and Xanodyne. Dr. Gersten receives or has received research funding from Amgen, Organon, Boehringer Ingelheim, Warner Chilcott, Duramed, Wyeth, Xanodyne, Bayer, Perrigo, and Ortho-McNeil. Dr. Hecht serves or has served on speakers' bureaus for Serono, Organon, and Wyeth and serves as a consultant for Xanodyne. He received travel or accommodations covered or reimbursed for his consulting work and as one of the investigators. Dr. Edlund receives or has received research support from Kabi Pharmacia, Pharmacia & Upjohn, and Ferring. He consults with Ferring, AstraZeneca, Bayer Schering, and Xanodyne. He has given expert testimony regarding U.S. Food and Drug Administration approval. Dr. Richter receives or has received research support or has acted as a consultant for University of California, San Francisco, Pfizer, Astellas Pharmaceuticals, and Xanodyne. Dr. Eder received research support from Church & Dwight Co, Bayer Healthcare, Ferring, Orasure Technology, Quatrx Pharmaceuticals, KV Pharmaceutical, Roche Molecular Systems, FemmePharma Global Healthcare, Inc., Warner Chilcott, TriPath Imaging, and Teva Pharmaceuticals. Dr. Patrick has acted as a consultant for Amgen, Meritage, Amylin, Pfizer and Merck. Dr. Rubin is a statistical consultant for Xanodyne. Dr. Attia did not disclose any potential conflicts of interest.
OBJECTIVE: To assess the efficacy and safety of an oral formulation of tranexamic acid for the treatment of heavy menstrual bleeding.
METHODS: Adult women with heavy menstrual bleeding (mean menstrual blood loss 80 mL or more per cycle) were enrolled in a double-blind, placebo-controlled study. After two pretreatment menstrual cycles, women were randomized to receive tranexamic acid 3.9 g/d or placebo for up to 5 days per menstrual cycle through six cycles. To meet the prespecified three-component primary efficacy end point, mean reduction in menstrual blood loss from baseline with tranexamic acid treatment needed to be 1) significantly greater than placebo, 2) greater than 50 mL, and 3) greater than a predetermined meaningful threshold (36 mL or higher). Health-related quality of life was measured using a validated patient-reported outcome instrument.
RESULTS: Women who received tranexamic acid (n=115) met all three primary efficacy end points: first, a significantly greater reduction in menstrual blood loss of −69.6 mL (40.4%) compared with −12.6 mL (8.2%) in the 72 women who received placebo (P<.001); reduction of menstrual blood loss exceeding a prespecified 50 mL; and last, reduction of menstrual blood loss considered meaningful to women. Compared with women receiving placebo, women treated with tranexamic acid experienced significant improvements in limitations in social or leisure and physical activities, work inside and outside the home, and self-perceived menstrual blood loss (P<.01). The majority of adverse events were mild to moderate in severity, and the incidence of gastrointestinal adverse events was comparable with placebo.
CONCLUSION: In this study, a new oral tranexamic acid treatment was well tolerated and significantly improved both menstrual blood loss and health-related quality of life in women with heavy menstrual bleeding.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00386308.
LEVEL OF EVIDENCE: I
Heavy menstrual bleeding is described as a condition that “interferes with the woman's physical, social, emotional, and/or material quality of life.”1 Although quantitatively defined as menstrual blood loss of 80 mL or more per menstrual cycle,2–4 the diagnosis of heavy menstrual bleeding is typically based on personal perception of menstrual blood loss and its effect on daily life. The negative effects of heavy menstrual bleeding on health-related quality of life (eg, limitations in daily activities, work functions, and social interactions) are what often lead women to seek medical treatment.5–9 Hormonal medications, nonsteroidal antiinflammatory drugs, and surgical procedures can effectively reduce menstrual blood loss; however, relative contraindications, variable efficacy, potential adverse effects, or undesired effects on fertility can limit the use of these therapies.10
Evidence of increased fibrinolytic activity in the menstrual blood of women with heavy menstrual bleeding prompted evaluation of hemostatic agents as potential therapeutic options.11,12 Having established efficacy in reducing menstrual blood loss, tranexamic acid, a competitive plasminogen inhibitor, has been used for treatment of heavy menstrual bleeding outside of the United States for several decades.13,14 Oral, immediate-release tranexamic acid is generally well tolerated; however, gastrointestinal adverse effects may limit its use.13 A unique oral formulation of tranexamic acid (LYSTEDA) that provides a higher per-tablet dose and increases drug absorption time has been designed to maintain efficacy while minimizing gastrointestinal adverse effects and was recently approved by the U.S. Food and Drug Administration for the treatment of cyclic heavy menstrual bleeding. In this report, we describe quantitative and qualitative results from a phase 3 clinical trial of this novel tranexamic acid formulation.
MATERIALS AND METHODS
In this multicenter, double-blind, parallel-group study, women with heavy menstrual bleeding were randomized to receive tranexamic acid (LYSTEDA) 1.3 g per dose (two tablets, 650 mg each) or matching placebo. Women were instructed to begin treatment at the onset of heavy menstrual bleeding and to take the study medication three times daily at least 6 hours apart for up to 5 days per cycle over the course of six menstrual cycles. The maximum daily dose of tranexamic acid was 3.9 g.
Adult women (age 18 to 49 years) with heavy menstrual bleeding were enrolled at 40 clinical sites in the United States. Participants were required to have a history of three or more consecutive days of heavy menstrual bleeding over at least four of their last six menstrual periods. During a two-cycle pretreatment baseline phase, menstrual blood loss had to be at least 60 mL during the first menstrual period and had to average at least 80 mL over both pretreatment cycles. Participants were required to have normal findings on pelvic examination, no clinically important cervical cytology abnormalities, and no clinically important uterine pathologic findings by transvaginal ultrasonography. The transvaginal ultrasonogram was considered abnormal if the endometrial thickness was greater than 12 mm or if the endometrial thickness was 5 to 12 mm and the patient's clinical history suggested long-term unopposed estrogen exposure (1 year or longer). If the transvaginal ultrasonogram was considered abnormal, normal results on endometrial biopsy were required. Presence of leiomyomas was not considered an abnormal finding unless the leiomyomas were of a sufficient number and size to warrant surgical management. In addition, participants had to have a history of regularly occurring menstrual periods of no more than 10 days in duration and 21 to 35 days from the start of one period until the start of the next menstrual period. Women of childbearing potential were required to use an acceptable nonhormonal method of birth control.
Women were excluded from the study if they had a history or presence of significant medical problems (eg, thromboembolic disease, coagulopathy, subarachnoid hemorrhage, endocrinopathy, or ocular disease); had severe anemia (hemoglobin less than 8 g/dL); were pregnant or lactating; had a history or presence of endometrial abnormalities or cervical carcinoma; or had anovulatory dysfunctional uterine bleeding, metrorrhagia, menometrorrhagia, or polymenorrhea. Participants were required to have normal color vision and could not have glaucoma, ocular hypertension, macular degeneration, or retinopathies (see Discussion for rationale).
Participants were not permitted to use anticoagulants, aspirin, dong quai, aminocaproic acid, or hydroxychloroquine during the study. Cyclooxygenase-2 inhibitors and nonsteroidal antiinflammatory drugs were not allowed during menstrual periods, but were permitted during the intermenstrual phase of the cycle. Use of acetaminophen, analgesic opioids, oral iron therapy, and vitamins was permitted throughout the study. Oral iron therapy was prescribed at the investigator's discretion for women with hemoglobin levels between 11 g/dL and 12 g/dL at baseline. Oral iron therapy was required for women with baseline hemoglobin levels lower than 11 g/dL and for those individuals whose hemoglobin levels declined to less than 11 g/dL during the study.
The protocol received approval from each site's Institutional Review Board and was conducted in compliance with the principles of the Declaration of Helsinki and guidelines for Good Clinical Practice. All participants provided signed informed consent.
The prespecified three-component primary efficacy end point was mean reduction in menstrual blood loss with tranexamic acid treatment that was 1) significantly greater than that of the placebo group, 2) greater than 50 mL from baseline, and 3) greater than a reduction in menstrual blood loss previously established to be perceived as meaningful to women (36 mL or higher; unpublished data). The change in menstrual blood loss was calculated by subtracting the mean blood loss during the two pretreatment cycles from the mean blood loss during four of the on-treatment cycles (first, second, third, and sixth cycles). Quantification of a “meaningful” change was performed by constructing a receiver operating characteristic curve based on change in menstrual blood loss from baseline data and responses to Menorrhagia Impact Questionnaire (MIQ) question 6 (see Table 1) in a separate, double-blind, placebo-controlled heavy menstrual bleeding study. Sensitivity and specificity were computed by dichotomizing the change in menstrual blood loss from baseline values as above and below various thresholds (cutoff points) in 1-mL increments and the MIQ question 6 responses as meaningful or not meaningful. The optimum balance of sensitivity and specificity was used as the minimum value for a meaningful improvement in menstrual blood loss.
Participants were instructed to collect and return all menses captured on sponsor-provided sanitary products for analysis; emphasis was placed on preventing loss of menstrual fluid. Individually labeled bags containing each woman's daily used sanitary products were shipped by the study sites to a central laboratory for quantification of menstrual blood loss. The volume of menstrual blood was objectively measured using a validated alkaline hematin method.15
Secondary end points included change from baseline in health-related quality-of-life parameters, the occurrence of large blood stains, and hemoglobin and ferritin concentrations. Qualitative health-related quality-of-life assessments were based on responses to the MIQ, a disease-specific, validated patient-reported outcome instrument (Table 1) that was completed by participants after all screening and treatment cycles. Among the parameters measured by the MIQ were limitations on social or leisure activities, limitations on physical activities, limitation in work outside or inside the home, and patient perception of treatment-induced changes in menstrual blood loss. The number and size of blood stains were recorded by participants in menstrual bleeding diaries. Hemoglobin and ferritin concentrations were determined from routine laboratory evaluations. Normal hemoglobin concentrations were defined as more than 12 g/dL and normal ferritin levels were defined as more than 10 ng/mL. Data for all prespecified secondary end points and additional secondary end points (with the exception of hemoglobin and ferritin levels) were collected during all study menstrual cycles. Blood samples for determining hemoglobin and ferritin concentrations were collected at baseline and treatment menstrual periods 3 and 6.
Medication safety was assessed by evaluating laboratory data, performing physical examinations, measuring vital signs, evaluating data from 12-lead electrocardiography, performing ophthalmologic examinations, and monitoring adverse events. Medication adherence was assessed by study personnel who reviewed participant study diaries and counted returned tablets.
The sample size was calculated using a two-to-one allocation and a 90% chance of detecting a 50-mL difference in the mean change in menstrual blood loss from baseline to end of study between groups. The standard deviation of ς=85 mL used in the calculation was derived from previous tranexamic acid studies.16–18 The sample size was based on a two-sided α=0.05 level of significance and assumed normal distribution of the data. An interim analysis by the Data Safety Monitoring Board resulted in an increase in the planned sample size by 28 participants (total 120 participants) in the tranexamic acid treatment group and 18 participants (total 64 participants) in the placebo treatment group to achieve appropriate power for detecting between-group differences in the prespecified secondary variables.
A randomization schedule was generated for packaging, labeling, and treatment group assignment using a permuted block randomization scheme. The randomization block size was eight, with five participants assigned to tranexamic acid and three participants assigned to placebo per block. Fisher Clinical Services was responsible for generating the randomization and allocation sequence and enrolling and assigning blinded study medication to individuals. Participants, investigators, sponsor, statisticians, clinical data management staff, and clinical monitors were blinded to study group allocation. Study drug was individually packaged for each visit and labeled with the study code. The tranexamic acid and placebo tablets were identical in appearance.
Efficacy analyses were conducted using data from the modified intent-to-treat population, which included participants who had sufficient data at baseline and for at least one treatment cycle. The primary efficacy analysis included a between-treatment group comparison using an analysis of covariance (ANCOVA) model and a within-treatment difference assessment using paired t tests for the mean change from baseline in menstrual blood loss. To address differences in baseline characteristics, baseline menstrual blood loss was used as a covariate in the ANCOVA analysis. The calculations of least-squares mean changes from baseline did not include adjustment for baseline menstrual blood loss. Treatment effect was confirmed using a linear regression analysis of menstrual blood loss over time by statistical testing of the significance and direction of the regression slope. Additional comparative treatment analyses included the percentage of menstrual cycles with 1) menstrual blood loss of 80 mL or less, 2) decrease of 36 mL or more in menstrual blood loss from baseline (calculated by receiver operating characteristic analysis to be the threshold for a meaningful reduction in menstrual blood loss), 3) 50-mL or more decrease in menstrual blood loss from baseline, and 4) 50% or more decrease in menstrual blood loss from baseline.
Prespecified secondary end-point analyses were performed under a sequential step-down procedure in the following order of importance: 1) changes in limitations on social or leisure activities scores, 2) changes in limitations on physical activities scores, and 3) large stain responder (percentage of participants with a decrease from baseline in the number of large stains). The sequence was fixed before unblinding. The hypotheses were to be tested at α=0.05 level of significance. If at any point of the testing sequence results were not statistically significant, then any remaining prespecified analyses were to be exploratory in nature. All secondary end points were comparisons of the mean of the two baseline cycles and the mean of the six treatment cycles. Between-treatment differences in the prespecified and other secondary end points were evaluated using ANCOVA, with the study group treatment cycle value and the baseline value included as covariates in their respective analyses. Using general linear models, least-squares means change (adjusted mean) was computed with the respective baseline health-related quality-of-life score as the covariate and reported as a positive value. The within-treatment test was conducted using a paired difference t test. The intraparticipant differences for the number of large stains were calculated as the average number of stains recorded during treatment minus the baseline average. The percentage of participants with a reduction from baseline in the number of large stains was compared between treatment groups using a two-tailed Fisher exact test.
Demographic and safety data were described using summary statistics. Analysis of variance was used to assess between-group differences in these parameters. Safety evaluations were conducted using data from the intent-to-treat population, which included all randomized participants who took at least one dose of study drug. All statistical analyses were performed using SAS 9.1.3.
A total of 196 participants were randomized to receive tranexamic acid (n=123) or placebo (n=73; Fig. 1). The intent-to-treat population consisted of 189 women, 117 in the tranexamic acid group and 72 in the placebo group. Six participants in the tranexamic acid group and 1 in the placebo group were excluded from the intent-to-treat analyses because they did not ingest at least one dose of study drug. The modified intent-to-treat population consisted of 187 women, 115 in the tranexamic acid group and 72 in the placebo group. Two individuals in the tranexamic acid group were excluded from the modified intent-to-treat analyses because posttreatment data were unavailable. In all, 148 women completed the study, 94 in the tranexamic acid group and 54 in the placebo group. Forty-eight participants withdrew from the study; the majority were lost to follow-up (16 individuals). Two participants in the placebo group and no individuals in the tranexamic acid group discontinued because of unsatisfactory efficacy response. The first participant was screened on October 16, 2006, and the last study visit was May 8, 2008.
Both groups had comparable baseline and demographic characteristics, with the exception of baseline menstrual blood loss (Table 2). Participants in the modified intent-to-treat population randomized to receive tranexamic acid (n=115) had a slightly higher baseline menstrual blood loss compared with the 72 women randomized to receive placebo (172.3±95.6 and 153.0±66.6 mL/cycle, respectively); however, the difference was not statistically significant (P=.11). The mean number of treatment days per cycle was 3.4 days for tranexamic acid and 3.3 days for participants taking placebo. Among the 188 individuals with treatment compliance data, 96.3% of tablets were taken in both treatment groups.
Women with heavy menstrual bleeding treated with tranexamic acid achieved the prespecified three-part primary efficacy outcome. A statistically significant reduction in mean menstrual blood loss occurred among women in the modified intent-to-treat population receiving tranexamic acid compared with those receiving placebo (−69.6 mL [40.4% reduction] compared with −12.6 mL [8.2% reduction]; P<.001), and the reduction in menstrual blood loss from baseline for those receiving tranexamic acid was greater than 50 mL and also exceeded the threshold of menstrual blood loss reduction (36 mL and greater) considered meaningful to women. Least-squares mean change in menstrual blood loss was also significantly greater in the tranexamic acid group (−66.3 mL [38.5% reduction]) compared with placebo group (−17.8 mL [11.6% reduction]; P<.001).
The reduction in menstrual blood loss from baseline with tranexamic acid use was reported by women after the first treatment cycle (Fig. 2) and this reduction was maintained in each measured treatment cycle (confirmed by linear regression analyses). Treatment of heavy menstrual bleeding with tranexamic acid was effective in reducing menstrual bleeding regardless of presence of leiomyomas or baseline menstrual blood loss (Fig. 3). The blood loss on treatment declined to less than 80 mL (standard definition of heavy menstrual bleeding) in 43% (181/426) of menstrual cycles in women receiving tranexamic acid, compared with 17% (43/254) of cycles in women receiving placebo (P<.001).
The percentage of cycles with clinically meaningful reduction in menstrual blood loss of at least 36 mL was greater with tranexamic acid treatment (69%) compared with placebo use (29%; P<.001). Further, a significantly greater percentage of menstrual cycles had a reduction of at least 50 mL in the tranexamic acid group (56%) compared with the placebo group (19%; P<.001). In terms of the percentage of menstrual blood loss reduction, the proportion of women with at least a 50% reduction of menstrual blood loss from baseline was greater in the tranexamic acid group (35%) compared with placebo (7%; P<.001).
Two of the three prespecified secondary end points were met by women receiving tranexamic acid. Mean improvements in scores for limitations on social or leisure activities and limitations on physical activities were significantly greater in the tranexamic acid group compared with the placebo group, respectively (P<.001; Fig. 4A). The change in least-squares means in scores for limitations on social or leisure activities (0.85±0.13 compared with 0.44±0.12; P<.001) and limitations on physical activities (0.87±0.13 compared with 0.40±0.14; P<.001) was significantly greater in the tranexamic acid group compared with placebo group, respectively. The percentage of women who experienced reductions in the number of large stains reported from baseline (large stain responder) was slightly higher among women treated with tranexamic acid than with placebo; however, the difference was not statistically significant (P=.45; Fig. 4B). Improvements in scores for limitations on social or leisure activities and limitations on physical activities were evident during the first treatment cycle and were maintained throughout the study (Fig. 5A and 5B). For women receiving tranexamic acid, scores for limitations on social or leisure activities and limitations on physical activities improved from “moderate impairment” at baseline to “slight impairment” after treatment.
Secondary end-point analyses revealed that participants in the tranexamic acid treatment group experienced a larger reduction (indicating improvement) in mean scores for limitation in work outside or inside the home compared with women taking placebo (−0.71±0.85 compared with −0.16±0.87, respectively; P<.001); improvements were evident during the first treatment cycle and were maintained throughout the study (Fig. 5C). Statistically significant between-group treatment differences were observed for mean changes in perceived menstrual blood loss scores from baseline (−0.47±0.59 and 0.15±0.67 for tranexamic acid and placebo participants, respectively, P<.001; Fig. 5D).
Anemia was more prevalent at baseline in the tranexamic acid group (33.9% [39/115]) than in the placebo group (18.1% [13/72]). Mean hemoglobin levels did not appreciably increase from baseline in the tranexamic acid treatment group (0.02±1.10 g/dL); a slight but statistically significant increase was observed in the placebo group (0.34±0.66 g/dL; P<.001); this change is not considered clinically significant. Mean changes from baseline ferritin concentrations were not significant in either group (−1.21±12.70 and −2.68±16.15 ng/mL for tranexamic acid and placebo groups, respectively).
This formulation of tranexamic acid was generally well tolerated, and the majority of adverse events in the intent-to-treat population were mild to moderate in severity. The most common adverse events reported were menstrual discomfort or cramps, headache, and back pain (Table 3). Sinus headache and anemia were reported more often with tranexamic acid use than with placebo. The frequency of gastrointestinal-related adverse events was similar between groups. Six serious adverse events were reported during the study: in the tranexamic acid group, one incident each of tachycardia, acute bronchitis, hypoglycemia, posttraumatic stress disorder, and urticaria; in the placebo group, one incident of deep vein thrombosis. All of these events were judged to be unrelated to study treatment. No thrombotic events were reported in the participants treated with tranexamic acid and no deaths occurred during the study. Seven study participants reported or experienced an ocular-related adverse effect that was considered possibly or probably treatment related; two of these individuals were receiving tranexamic acid and five were receiving placebo. In the tranexamic acid group, a woman missed one blue-yellow color vision plate (right eye) during an eye examination and another woman complained of a nonspecific visual disturbance; these conditions were not considered clinically significant. No clinically significant changes in blood pressure, pulse rate, physical or gynecologic findings, or electrocardiograph parameters were observed during the study.
In this phase 3 trial, a new oral tranexamic acid formulation provided quantitative and qualitative relief for women with heavy menstrual bleeding. In terms of menstrual blood loss, the three-part primary efficacy end point was achieved in significantly more women treated with tranexamic acid than with placebo, and tranexamic acid treatment resulted in consistent improvement irrespective of baseline menstrual blood loss or the presence of uterine leiomyomas. More than two thirds of women treated with tranexamic acid experienced clinically meaningful reductions in menstrual blood loss (36 mL and greater), with a significantly greater proportion of tranexamic acid–treated menstrual cycles reaching menstrual blood loss volumes within the normal range (less than 80 mL) compared with placebo. Moreover, women receiving tranexamic acid reported statistically and, most likely, clinically significant improvements in health-related quality-of-life parameters compared with those receiving placebo. Improvements in both menstrual blood loss and health-related quality-of-life parameters were observed during the first treatment cycle and were maintained throughout the 6-month study duration.
Quantitative measurements of menstrual blood loss used in clinical trials are typically not practical in routine clinical care, as women are required to collect and return all menses captured on sanitary products for laboratory analysis. Previous studies had suggested that tranexamic acid improves health-related quality of life in women with heavy menstrual bleeding, although limitations in study design (eg, open-label, nonspecific health-related quality-of-life assessment tool, lack of a placebo group) hindered interpretation of clinical relevance.19–21 By using a validated patient-reported outcomes tool in a placebo-controlled, double-blind study, we feel that the statistically significant improvements in health-related quality of life with tranexamic acid compared with placebo in our study represent a clinically significant and meaningful finding for women with heavy menstrual bleeding.
Mean hemoglobin or ferritin levels did not appreciably improve from baseline in the tranexamic acid treatment group and were not significantly different from the placebo group. These findings may be due in part to the use of oral iron therapy in individuals with low baseline hemoglobin and ferritin levels, the greater number of participants in the tranexamic acid group with anemia at baseline, and the higher mean baseline menstrual blood loss measured in the placebo group. In addition, changes in hemoglobin and ferritin concentrations are more likely to be observed over the long term (more than 6 months) in a population with chronic cyclic heavy menstrual bleeding such as ours (mean duration of heavy menstrual bleeding, 10 years). Future studies should assess the long-term efficacy of tranexamic acid.
The formulation of tranexamic acid used in this study was well tolerated. Previous studies of an immediate-release tranexamic acid formulation indicate that therapy-limiting gastrointestinal adverse effects occurred.16,22 The novel, oral formulation of tranexamic acid studied here was designed to decrease the rate of drug delivery to the gastric mucosa and therefore facilitate gastrointestinal tolerability. In the current study, the frequency of gastrointestinal-related adverse events was comparable between tranexamic acid and placebo groups. Eye examinations were included in our evaluation of safety because focal areas of retinal degeneration have been observed in animal studies of intravenous tranexamic acid and visual abnormalities have been noted in postmarketing surveys. Treatment-related ocular findings in this study were not considered clinically significant.
In women with heavy menstrual bleeding, tranexamic acid appears to stabilize the deposition of endometrial vascular wall fibrin that occurs with menstruation,13 but is unlikely to increase thrombosis. Thrombosis has not been observed in men or women receiving tranexamic acid for the management of bleeding secondary to cardiac or oral surgery, acute upper gastrointestinal bleeding, or ocular trauma,13,14,23 and the use of tranexamic acid is not associated with an increased risk or incidence of thromboembolic events compared with the background rate of thrombotic events in women of childbearing age.14,24,25 The results from the tranexamic acid clinical program, including a long-term, open-label safety study in women treated with tranexamic acid for up to 27 months (data not shown), support these studies and retrospective evaluations. Although one thrombotic event was reported in this clinical study, it occurred in a participant receiving placebo.
One limitation of the study was the prohibition of certain medications during the entire study period (eg, hormonal contraceptives) or during the women's menstrual cycle (eg, nonsteroidal antiinflammatory drugs, cyclooxygenase-2 inhibitors) to avoid potential confounding effects on menstrual blood loss or adverse events12 (Mirena package insert, Bayer HealthCare Pharmaceuticals, Wayne, NJ, October 2009). Additional data are needed to determine whether concomitant use of these medications with tranexamic acid would influence the risk of certain adverse events.
In the current study, use of tranexamic acid significantly reduced menstrual blood loss from baseline and improved health-related quality of life while maintaining safety and tolerability. The adverse events were predominantly mild to moderate, with an incidence of gastrointestinal events that was comparable with placebo. Tranexamic acid offers a first-line, nonhormonal, nonsurgical treatment option for women with cyclic heavy menstrual bleeding that may become an important alternative to surgical procedures and medical treatments.
1.National Institute for Health and Clinical Excellence. NICE clinical guideline 44: heavy menstrual bleeding. London (UK): National Health Service; January 2007.
2.Hallberg L, Högdahl AM, Nilsson L, Rybo G. Menstrual blood loss: a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966;45:320–51.
3.Rees M. Menorrhagia. Br Med J (Clin Res Ed) 1987;294:759–62.
4.Wyatt KM, Dimmock PW, Walker TJ, O'Brien PM. Determination of total menstrual blood loss. Fertil Steril 2001;76:125–31.
5.Coulter A, Peto V, Jenkinson C. Quality of life and patient satisfaction following treatment for menorrhagia. Fam Pract 1994;11:394–401.
6.Liu Z, Doan QV, Blumenthal P, Dubois RW. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Value Health 2007;10:183–94.
7.Shankar M, Chi C, Kadir RA. Review of quality of life: menorrhagia in women with or without inherited bleeding disorders. Haemophilia 2008;14:15–20.
8.de Souza SS, Camargos AF, Ferreira MC, de Assis Nunes Pereira F, de Rezende CP, Araújo CA, et al. Hemoglobin levels predict quality of life in women with heavy menstrual bleeding. Arch Gynecol Obstet 2010;281:895–900.
9.Shapley M, Jordan K, Croft PR. Why women consult with increased vaginal bleeding: a case-control study. Br J Gen Pract 2002;52:108–13.
10.Hurskainen R, Grenman S, Komi I, Kujansuu E, Luoto R, Orrainen M, et al. Diagnosis and treatment of menorrhagia. Acta Obstet Gynecol Scand 2007;86:749–57.
11.Dockeray CJ, Sheppard BL, Daly L, Bonnar J. The fibrinolytic enzyme system in normal menstruation and excessive uterine bleeding and the effect of tranexamic acid. Eur J Obstet Gynecol Reprod Biol 1987;24:309–18.
12.Fraser IS, Porte RJ, Kouides PA, Lukes AS. A benefit-risk review of systemic haemostatic agents: part 2: in excessive or heavy menstrual bleeding. Drug Saf 2008;31:275–82.
13.Wellington K, Wagstaff AJ. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs 2003;63:1417–33.
14.Rybo G. Tranexamic acid therapy: effective treatment in heavy menstrual bleeding. Clinical update on safety. Ther Adv 1991;4:1–8.
15.Hallberg L, Nilsson L. Determination of menstrual blood loss. Scand J Clin Lab Invest 1964;16:244–8.
16.Preston JT, Cameron IT, Adams EJ, Smith SK. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol 1995;102:401–6.
17.Edlund M, Andersson K, Rybo G, Lindoff C, Astedt B, von Schoultz B. Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi 2161). Br J Obstet Gynaecol 1995;102:913–7.
18.Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 1996;313:579–82.
19.Winkler UH. The effect of tranexamic acid on the quality of life of women with heavy menstrual bleeding. Eur J Obstet Gynecol Reprod Biol 2001;99:238–43.
20.Kouides PA, Byams VR, Philipp CS, Stein SF, Heit JA, Lukes AS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol 2009;145:212–20.
21.Srinil S, Jaisamrarn U. Treatment of idiopathic menorrhagia with tranexamic acid. J Med Assoc Thai 2005;88:S1–6.
22.Gleeson NC, Buggy F, Sheppard BL, Bonnar J. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand 1994;73:274–7.
23.Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999;57:1005–32.
24.Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost 2001;86:714–5.
25.Lindoff C, Rybo G, Astedt B. Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb Haemost 1993;70:238–40.
Figure. No caption available.
Supplemental Digital Content
© 2010 by The American College of Obstetricians and Gynecologists.